| 3.8 -3 (-44.12%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.33 |
1-year : | 6.23 |
| Resists | First : | 4.57 |
Second : | 5.33 |
| Pivot price | 0.33 |
|||
| Supports | First : | 1.77 |
Second : | 0.04 |
| MAs | MA(5) : | 0.81 |
MA(20) : | 0.26 |
| MA(100) : | 0.2 |
MA(250) : | 0.35 |
|
| MACD | MACD : | 0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 37.5 |
D(3) : | 28.4  |
| RSI | RSI(14): 98.1 |
|||
| 52-week | High : | 4.57 | Low : | 0.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SBFM ] has closed above the upper band by 43.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 2966.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.58 - 4.6 | 4.6 - 4.62 |
| Low: | 3.16 - 3.18 | 3.18 - 3.2 |
| Close: | 3.76 - 3.8 | 3.8 - 3.83 |
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Fri, 12 Apr 2024
Sunshine Biopharma announces reverse stock split By Investing.com - Investing.com
Fri, 12 Apr 2024
Sunshine Biopharma Announces Reverse Stock Split - Yahoo Canada Finance
Tue, 02 Apr 2024
Sunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Mon, 01 Apr 2024
Sunshine Biopharma's Strong Growth and Optimistic Outlook - TipRanks.com - TipRanks
Mon, 01 Apr 2024
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 - Yahoo Finance
Thu, 14 Mar 2024
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 99 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 9.4 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 707 (K) |
| Shares Short P.Month | 445 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | -18.8 % |
| Operating Margin | -15.5 % |
| Return on Assets (ttm) | -10.6 % |
| Return on Equity (ttm) | -21.1 % |
| Qtrly Rev. Growth | 94.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.24 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -20 |
| PEG Ratio | 0 |
| Price to Book value | 5 |
| Price to Sales | 15.68 |
| Price to Cash Flow | -43.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|